Mayne Banks On Nextstellis As Generics Business Suffers
Company Sees 6% Decline In Revenues But Dermatology Portfolio Continues To Grow
Mayne Pharma has expressed confidence after its recent US launch of Nextstellis (estetrol/drospirenone) 14.2mg/3mg oral contraceptive tablets. While the firm’s overall sales dipped by 6% in its financial first half, Mayne expects its recent and near-term launches, particularly key dermatology products, to help reverse the trend.
